Format

Send to

Choose Destination
Thromb Res. 2019 Jun;178:124-131. doi: 10.1016/j.thromres.2019.04.016. Epub 2019 Apr 17.

Impact of risk factors on the occurrence of arterial thrombosis and venous thromboembolism in adults with primary immune thrombocytopenia - Results from two nationwide cohorts.

Author information

1
Centre for Pharmacoepidemiology, Department of Medicine, Solna, Karolinska Institutet, Sweden. Electronic address: charlotta.ekstrand@ki.se.
2
Centre for Pharmacoepidemiology, Department of Medicine, Solna, Karolinska Institutet, Sweden.
3
Clinical Investigation Center, 1436, Toulouse, Toulouse University Hospital, France.
4
UMR 1027 INSERM, University of Toulouse, Toulouse, France; Department of Medical and Clinical Pharmacology, Toulouse University Hospital, France.
5
UMR 1027 INSERM, University of Toulouse, Toulouse, France; Department of Internal Medicine, Toulouse University Hospital, France; Clinical Investigation Center, 1436, Toulouse, Toulouse University Hospital, France.
6
UMR 1027 INSERM, University of Toulouse, Toulouse, France; Clinical Investigation Center, 1436, Toulouse, Toulouse University Hospital, France; Department of Medical and Clinical Pharmacology, Toulouse University Hospital, France.
7
Centre for Pharmacoepidemiology, Department of Medicine, Solna, Karolinska Institutet, Sweden; Department of Laboratory Medicine, Karolinska Institutet, Sweden.

Abstract

BACKGROUND:

Previous studies have found that patients with Immune thrombocytopenia (ITP) have an increased risk of arterial thrombosis (AT) and venous thromboembolism (VTE). However, risk factors for thrombosis in adults with primary ITP remain unassessed in large cohorts. Aim To assess the occurrence and impact of risk factors for AT and VTE in patients with primary ITP in France and Sweden.

METHODS:

Both countries have national health databases, including hospital diagnoses and drug dispensing data. Adults with incident primary ITP identified using algorithms between the years 2009-2015 in France, and 2009-2016 in Sweden were included. Cumulative incidence rates (IR) of AT and VTE were calculated by risk factors and multivariable Cox models were used to estimate associations.

RESULTS:

The study included 7225 patients from France and 2490 from Sweden. The IR of AT were 15.0 (95% CI: 13.4-16.7) and 14.7 (95% CI: 12.4-17.5) per 1000 person-years, respectively. The incidences of VTE were 6.9 (95% CI: 5.9-8.1) and 6.5 (95% CI: 5.1-8.4), respectively. Increasing age, male sex and a previous AT were associated with AT in both countries and so were exposure to antiplatelet drugs in France and a history of VTE and chronic kidney disease in Sweden. Increasing age and a history of VTE were associated with VTE in both countries, in France also cancer.

CONCLUSION:

The IR of AT and VTE were similar in France. Age and male sex remained the most important risk factors for AT, age for VTE.

KEYWORDS:

Arterial thrombosis; ITP; Risk factors; Venous thromboembolism

PMID:
31026663
DOI:
10.1016/j.thromres.2019.04.016
Free full text

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center